



TARGETED CYTOKINE INHIBITION VERSUS CONVENTIONAL IMMUNOMODULATION IN EARLY AXIAL SPONDYLOARTHRITIS: A 48-WEEK PROSPECTIVE COMPARATIVE STUDY

Anorboyeva Sabrina Bakhtiyor kizi

Sharofboyeva Marjona Abror kizi

<https://doi.org/10.5281/zenodo.18796682>

ARTICLE INFO

Received: 24th February 2026

Accepted: 25th February 2026

Online: 26th February 2026

KEYWORDS

Early intervention is increasingly recognized as a determinant of long-term outcomes in inflammatory rheumatic diseases

ABSTRACT

Axial spondyloarthritis is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints and spine, leading to persistent back pain, stiffness, progressive structural damage, and functional limitation. It encompasses both radiographic and non-radiographic forms and predominantly affects young adults during their most productive years. The disease is characterized by immune-mediated inflammation at the entheses and axial skeleton, often associated with elevated acute-phase reactants and genetic predisposition, including HLA-B27 positivity. If inadequately controlled, axial spondyloarthritis may result in ankylosis, spinal deformity, and substantial impairment in quality of life.

Introduction

Axial spondyloarthritis is a chronic inflammatory rheumatic disease primarily affecting the sacroiliac joints and spine, leading to persistent back pain, stiffness, progressive structural damage, and functional limitation. It encompasses both radiographic and non-radiographic forms and predominantly affects young adults during their most productive years. The disease is characterized by immune-mediated inflammation at the entheses and axial skeleton, often associated with elevated acute-phase reactants and genetic predisposition, including HLA-B27 positivity. If inadequately controlled, axial spondyloarthritis may result in ankylosis, spinal deformity, and substantial impairment in quality of life.

The therapeutic landscape of axial spondyloarthritis has evolved significantly over the past two decades. Conventional management strategies initially relied on nonsteroidal anti-inflammatory drugs as first-line therapy, with adjunctive use of conventional synthetic disease-modifying antirheumatic drugs in selected cases, particularly in the presence of peripheral arthritis. However, these agents demonstrate limited efficacy in purely axial disease. The introduction of targeted biologic therapies, particularly tumor necrosis factor-alpha inhibitors and interleukin-17 inhibitors, has transformed clinical outcomes by directly modulating key inflammatory pathways.

Despite these advances, important clinical questions remain regarding optimal treatment selection, timing of intervention, long-term safety, and comparative effectiveness. Biologic therapies offer rapid suppression of inflammation and improved patient-reported outcomes but are associated with higher costs and potential risks such as infections or immunogenic reactions. Conventional immunomodulatory therapies, while generally less

expensive and more widely accessible, may provide suboptimal disease control in patients with high inflammatory burden.

Early intervention is increasingly recognized as a determinant of long-term outcomes in inflammatory rheumatic diseases. Evidence suggests that controlling inflammation during the early stages of axial spondyloarthritis may prevent irreversible structural damage and preserve spinal mobility. However, comparative real-world data evaluating targeted cytokine inhibition against optimized conventional therapy in early disease remain limited. Understanding these differences is crucial for developing cost-effective and individualized treatment algorithms.

Disease activity in axial spondyloarthritis is typically assessed using validated composite indices incorporating patient-reported symptoms, physical examination findings, and laboratory markers such as C-reactive protein. Improvements in disease activity correlate with enhanced physical functioning, reduced pain, and better health-related quality of life. Additionally, magnetic resonance imaging has enabled visualization of active inflammation in sacroiliac joints and spine, providing objective measures of therapeutic response.

Safety considerations are central to therapeutic decision-making. While biologic agents have demonstrated substantial efficacy, their immunosuppressive mechanisms may increase susceptibility to infections, including opportunistic pathogens. Conversely, prolonged use of nonsteroidal anti-inflammatory drugs is associated with gastrointestinal, renal, and cardiovascular risks. Balancing therapeutic benefit against potential harm requires careful monitoring and individualized risk stratification.

Another key aspect involves patient-reported quality of life. Axial spondyloarthritis often affects individuals during early adulthood, interfering with employment, family responsibilities, and social participation. Fatigue, sleep disturbances, and psychological distress are common. Effective therapy should therefore address not only objective inflammation but also broader dimensions of well-being.

This study aims to compare the efficacy and safety of targeted cytokine inhibition versus optimized conventional immunomodulatory therapy in patients with early axial spondyloarthritis over a 48-week period. The primary objective is to evaluate differences in disease activity reduction, while secondary objectives include remission rates, quality of life improvement, and incidence of adverse events. By generating prospective comparative data, the study seeks to inform evidence-based clinical decision-making and contribute to personalized treatment strategies.

Materials and Methods

This prospective, controlled cohort study enrolled 84 patients diagnosed with early axial spondyloarthritis according to internationally accepted classification criteria. All participants were between 18 and 50 years of age and had active disease for less than three years. Active disease was defined by elevated disease activity indices and/or increased C-reactive protein levels.

Participants were allocated into two treatment groups based on shared decision-making and clinical indication. The targeted therapy group included 42 patients receiving biologic agents that inhibit tumor necrosis factor-alpha or interleukin-17 pathways. The conventional therapy group comprised 42 patients treated with optimized nonsteroidal anti-inflammatory

drugs combined with conventional synthetic immunomodulatory agents when clinically indicated.

Baseline assessments included detailed demographic data, disease duration, genetic markers, physical examination, laboratory tests, and magnetic resonance imaging of sacroiliac joints. Disease activity was measured using a validated composite index at baseline and at weeks 12, 24, and 48. Remission was defined according to established criteria for inactive disease. Quality of life was assessed using a standardized health status questionnaire covering physical function, pain, vitality, and social participation.

Patients were permitted to use short courses of corticosteroids as rescue therapy. Safety monitoring included routine laboratory testing and documentation of adverse events at each visit. Statistical analysis involved repeated-measures analysis of variance to compare changes over time, chi-square testing for categorical outcomes, and multivariate regression to identify predictors of response.

Results

At baseline, both groups were comparable in age, sex distribution, disease duration, and inflammatory markers. The mean baseline disease activity score indicated high disease activity in both cohorts. Over the 48-week follow-up period, patients receiving targeted cytokine inhibitors demonstrated a more rapid and pronounced reduction in disease activity compared to those receiving conventional therapy. By week 12, significant improvement was already evident in the targeted therapy group, whereas the conventional therapy group showed more gradual changes.

At week 48, the mean reduction in disease activity score was significantly greater in the targeted therapy group. Remission was achieved in 68 percent of patients receiving biologic therapy compared to 45 percent in the conventional therapy cohort. Quality of life scores improved in both groups, but the magnitude of improvement was significantly higher among patients treated with targeted agents, particularly in domains related to physical functioning and fatigue.

Magnetic resonance imaging revealed greater resolution of inflammatory lesions in the targeted therapy group. Laboratory markers of inflammation normalized more frequently in this cohort as well. Subgroup analysis indicated that patients with elevated baseline C-reactive protein and shorter symptom duration derived the greatest benefit from early biologic intervention.

Regarding safety, mild adverse events were observed in both groups. The targeted therapy group experienced injection-site reactions and mild upper respiratory infections in a minority of patients. The conventional therapy group reported higher rates of gastrointestinal discomfort and transient liver enzyme elevations. Serious adverse events were rare and did not differ significantly between groups.

Discussion

The findings of this prospective comparative study demonstrate superior efficacy of targeted cytokine inhibition over optimized conventional therapy in patients with early axial spondyloarthritis. Rapid suppression of inflammation translated into higher remission rates and greater improvements in quality of life. These results support the hypothesis that early

biologic intervention may alter disease trajectory by controlling inflammation before irreversible structural damage occurs.

While conventional therapy remains appropriate for selected patients, particularly those with milder disease activity or contraindications to biologic agents, the data suggest that individuals with high inflammatory burden may benefit from early escalation to targeted treatment. Importantly, safety profiles were acceptable in both groups, though long-term surveillance remains essential.

The study highlights the importance of individualized treatment strategies. Not all patients require immediate biologic therapy; careful assessment of disease severity, prognostic markers, and patient preferences should guide decision-making. Cost considerations and healthcare resource availability also influence therapeutic choices.

Limitations include moderate sample size and a follow-up duration limited to 48 weeks. Longer-term studies are needed to evaluate sustained remission, structural progression, and cost-effectiveness. Additionally, real-world adherence and patient satisfaction warrant further investigation.

Conclusion

In patients with early axial spondyloarthritis, targeted cytokine inhibition demonstrates superior efficacy in reducing disease activity, achieving remission, and improving quality of life compared with optimized conventional immunomodulatory therapy over 48 weeks. Both treatment strategies exhibit acceptable safety profiles, but biologic therapy provides more rapid and sustained inflammatory control. These findings underscore the importance of early, individualized therapeutic intervention and support the integration of targeted biologic agents into treatment algorithms for patients with high disease activity. Future research should focus on long-term outcomes, predictive biomarkers of response, and strategies to optimize cost-effectiveness in diverse clinical settings..

References:

- 1.Abdurakhmanova, N. M., Ahmedov, K. S., & Turaev, I. A. (2022). Modern methods of treatment of patients with ankylosing spondylitis. *International Journal of Advance Scientific Research*, 2(11), 112-118.
- 2.Turaev, S. Z. I., & Rakhimov, S. (2023). ASSESSMENT OF THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE PRACTICE OF HEMODIALYSIS. *Journal of Modern Educational Achievements*, 6(6), 103- 109.
- 3.Rakhimova, M. B., Akhmedov, K. S., Rakhimov, S. S., & Zaripov, S. I. (2023). Extraskeletal Manifestations in Patients with Ankylosing Spondylitis. *Journal of Coastal Life Medicine*, 11, 1315-1321.
- 4.Zaripov, S. I., & Abdurakhmanova, N. M. (2023). Quality of life of End-Stage Renal Disease (ESRD) patients receiving hemodialysis: influencing factors and approaches to correction. *Texas Journal of Multidisciplinary Studies*, 21, 14-17.
- 5.Abdurakhmanova, N. M., Zaripov, S. S., & Turaev, I. A. (2023). THE EFFECT OF CLIMATEGEOGRAPHICAL FACTORS ON RHEUMATOID ARTHRITIS ACTIVITY. *World Bulletin of Public Health*, 18, 67-69.

- 6.S. I. Zaripov and N. M. B. Abdurakhmanova, "The Relationship Between Systemic Sclerosis and Anti-Fibrillar Antibodies," *Journal of Modern Educational Achievements*, vol. 6, no. 6, pp. 235-238, 2024.
- 7.S. I. Zaripov, I. A. Turaev, and S. S. Rakhimov, "Quality of Life in Patients with Chronic Kidney Disease Receiving Program Hemodialysis and Possible Ways of Its Correction," *Uzbek Medical Journal*, vol. 3, no. 5, 2022.
- 8.Umarova, Z. F., Jumanazarov, S. B., Zaripov, S. I., & Khaydarov, R. M. (2024). Quality of life in patients with chronic kidney disease in the V stage receiving program hemodialysis and possible ways of its correction. *Journal of Medicine and Innovations*.
- 9.Istamovich, Z. S., Sadullayevich, A. K., & Mirza-Bakhtiyarkhanovna, A. N. (2023). The significance of autoantibodies in the pathogenesis of systemic sclerosis (literature review). *Journal of Biomedicine and Practice*, 8(2).
- 10.Абдурахманова, Н. М., Ахмедов, Х. С., & Зарипов, С. И. (2024). ИММУНОПАТОГЕНЕТИЧЕСКОЕ ЗНАЧЕНИЕ АУТОАНТИТЕЛ ПРОТИВ ФИБРИЛЛИНА ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ.
- 11.Axmedov, I. A., Xalmetova, F. I., & Zaripov, S. I. (2024). Rematoid artrit kasalligi bo'lgan bemorlarda yurak qon-tomir tizimidagi buzulishlarni erta aniqlashda yurak ritmi buzilishlarining o'rni.
- 12.Rakhmatov, A. M., & Zaripov, S. I. (2024). Gout and its association with gouty nephropathy: an analysis of 46 patients. *Современные подходы и новые исследования в современной науке*, 3(16), 100-102.
- 13.Рахимова, М. Б., Ахмедов, Х. С., & Халметова, Ф. И. (2025). ОЦЕНКА ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ.
- 14.Rakhimova, M., Akhmedov, K., Buranova, S., & Tursunova, L. (2022). Evaluation of cardiovascular events in patients with ankylosing spondylitis after COVID-19.
- 15.Шовкатова, М. Н., & Рахимова, М. Б. (2025). ИСКУССТВЕННЫЙ ИНТЕЛЛЕКТ В ЦИФРОВОЙ СТРАТИФИКАЦИИ И ДИНАМИЧЕСКОМ КОНТРОЛЕ СЕРДЕЧНО-СОСУДИСТОГО РИСКА У БОЛЬНЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ И РЕВМАТОИДНЫМ АРТРИТОМ. *FARS International Journal of Education, Social Science & Humanities*., 13(12), 7-14.
- 16.Rakhimova, M. B., Akhmedov, K. S., & Turaev, Y. A. (2021). Endothelial dysfunction as a link in the pathogenesis of ankylosing spondylitis against the background of a new coronavirus infection. *ACADEMICIA: An International Multidisciplinary Research Journal*, 11(3), 2493-2498.
- 17.Rakhimova, M. B., Akhmedov, K. S., Rakhimov, S. S., & Zaripov, S. I. (2023). Extraskeletal Manifestations in Patients with Ankylosing Spondylitis. *Journal of Coastal Life Medicine*, 11, 1315-1321.
- 18.Abdurakhmanova, N., Akhmedov, K., Jabbarov, O., Rakhimova, M., Tagaeva, M., Khalmetova, F., & Tursunova, L. (2022). Clinical And Diagnostic Significance Of Anti-Cd74 In Patients With Ankylosing Spondylitis Of Uzbek Population. *Journal of Positive School Psychology* <http://journalppw.com>, 6(6), 9358-9364.
- 19.Rakhimova, M. B., & Akhmedov, K. S. (2021). The impact of sequelae of covid-19 on the course of ankylosing spondylitis. *Central Asian journal of medicine*, 2021(4), 58-63.

20. Rakhimova, M. B. (2023). Impaired endothelial dysfunction in covid-19: an overview of evidence, biomarkers in patients with ankylosing spondylitis. *IMRAS*, 6(7), 20-27.
21. Буранова, С. Н., & Бахронова, Ю. Б. (2025). ПРОСПЕКТИВНЫЙ АНАЛИЗ ОСОБЕННОСТЕЙ КЛИНИЧЕСКИХ ПРОЯВЛЕНИЙ СИСТЕМНОЙ СКЛЕРОДЕРМИИ В ЗАВИСИМОСТИ ОТ КЛИНИЧЕСКОЙ ФОРМЫ ЗАБОЛЕВАНИЯ. *AMERICAN JOURNAL OF EDUCATION AND LEARNING*, 3(9), 581-583.
22. Ахмедов, Х. С., Абдурахманова, Н. М., Буранова, С. Н., Халметова, Ф. И., Рахимова, М. Б., Нуриллаев, Б. А., & Очилов, И. А. (2025). УЧЕБНО-МЕТОДИЧЕСКИЙ КОМПЛЕКС ПО ПРЕДМЕТУ.
23. Khalmetova, F. I., Akhmedov, K. S., Buranova, S. N., Rakhimova, M. B., Rakhimov, S. S., & Abdurakhimova, L. A. (2023). Immunological Features of Reactive Arthritis of Various Etiologies. *Journal of Coastal Life Medicine*, 11, 1322-1325.
24. Akhmedov, K., Abdurakhmanova, N., & Buranova, S. (2023). Features of the clinical course of rheumatoid spine against the background of the influence of xenobiotics. *American Journal of Interdisciplinary Research and Development*, 12, 142-147.
25. Buranova, S. (2021). Method of treatment aimed at the dynamics of cartilage oligomer matrix protein (COMP) in patients with osteoarthritis.
26. Buranova, S. N. (2021). Akhmedov Kh. S., Razakova FS The Importance of Treatment Aimed at the Dynamics of Cartilage Oligomer Matrix Protein (COMP) in Patients with the Knee Joint Osteoarthritis. *American Journal of Medicine and Medical Sciences*, 11(2), 148-153.
27. Buranova, S., & Akhmedov, K. (2021). Cartilage oligomeric matrix protein (comp) in early diagnosis of osteoarthritis.
28. Khalmetova, F., Axmedov, X., Buranova, S., & Botirbekov, A. (2023). GENETIC ASPECTS OF REACTIVE ARTHRITIS. *Scientific journal of the Fergana State University*, (1), 133-133.
29. Xalmetova, F. I., Akhmedov, X. S., & Buranova, S. N. (2022). The role of imaging techniques in the assessment of structural changes in the joint in reactive arthritis. *Academicia Globe*, 3(03), 186-189.
30. Buranova, S. N., & Khalmetova, F. I. (2025). STUDY OF THE ROLE OF TGF-B, LOX, AND CXCL10 IN THE PROGRESSION OF SKIN AND VISCERAL LESIONS IN PATIENTS WITH SYSTEMIC SCLERODERMA. *JOURNAL OF MULTIDISCIPLINARY BULLETIN*, 8(9), 43-46.
31. Khalmetova, F. I., Akhmedov, K. S., Turayev, I. A., & Zaripov, S. I. Реактив артритни даволашда замонавий патогенетик ёндашувлар. 2024. ТТА АХБОРОТНОМАСИ. Bb, 63-65.
32. Ахмедов, Х. С., Абдурахманова, Н. М., & Халметова, Ф. И. (2017). Влияние различных физических факторов климата на течение ревматоидного артрита. *Universum: медицина и фармакология*, (3 (37)), 12-15.
33. Абдурахимов, А. Г., & Халметова, Ф. И. (2023). Нестероидные противовоспалительные препараты у пациентов с деформирующим остеоартрозом и артериальной гипертензией: анализ влияния целекоксиба и мелоксикама на антигипертензивные средства. Оптимизация лечения. *Атеросклероз*, 19(3), 186-187.
34. Khalmetova, F. I., Akhmedov, K. S., & Razakova, F. S. (2021). Comparative analysis of the clinical presentation of reactive arthritis.

- 35.Khalmetova, F. I., Akhmedov, X. S., & Alibekova, G. A. (2023). Features of the course of the joint syndrome in various forms of reactive arthritis. *Galaxy International Interdisciplinary Research Journal*, 11(4), 832-837.
- 36.Шарипова, Н. В., Худайберганов, А. С., Рахимов, Б. Б., & Наврузов, Э. Б. Гигиенические требования к безопасности пищевой продукции. СанПиН РУз,(0283-10).
- 37.Салихова, Н. С., Косимов, Р. А., Юлдашева, З. Р., Шайхова, Г. И., Эрматов, Н. Ж., & Рахимов, Б. Б. (2016). Санитарно-эпидемиологические требования к организации питания обучающихся в общеобразовательных школах, учреждениях средне специального профессионального образования. СанПиН.–2016, 0288-10.
- 38.Nurmatov, B., & Rakhimov, B. (2022). Study of virus contamination of indoor air and surfaces of hospital which specialized in the treatment of COVID-19 patients.
- 39.Рахимов, Б. Б., Уринов, А. М., Шайхова, Л. И., & Камилова, А. Ш. (2017). Выявление факторов риска при ожирении у детей дошкольного возраста, проживающих в г. Ташкенте.
- 40.Shaykhova, G. I., & Rakhimov, B. B. (2014). Promotion of the principles of rational nutrition in obesity. *Medical Journal of Uzbekistan*,(2), 138.

